Asciminib is used in the treatment of chronic myeloid leukemia (CML), particularly for patients who have developed resistance or intolerance to other tyrosine kinase inhibitors (TKIs). It works by targeting the ABL1 kinase domain in a unique allosteric manner, which helps in overcoming resistance caused by mutations in the ATP-binding site. This makes it a valuable option for patients who have failed previous therapies. Additionally, its specific mechanism of action reduces off-target effects, potentially leading to fewer side effects compared to traditional TKIs. It is often prescribed when other treatments are no longer effective or suitable for the patient.